Tags

Type your tag names separated by a space and hit enter

Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.
World J Mens Health. 2020 Mar 09 [Online ahead of print]WJ

Abstract

As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically significant weight loss. Increasing evidence has shown that behavior-based interventions with one of these medications can result in greater weight loss than that elicited by usual care conditions. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). However, they have a high cost and may cause adverse outcomes depending on the individual. Very recently, on February 13, 2020, the US Food and Drug Administration requested withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. Therefore the decision to initiate drug therapy in obese individuals should be made after the benefits and risks are considered. Thereafter, treatment should be tailored to specific patient subpopulations depending on their chronic conditions, comorbidities, and preferences. Herein, we provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control.

Authors+Show Affiliations

Department of Family Medicine, Pusan National University School of Medicine, Yangsan, Korea. Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.Family Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea. Department of Medical Education, Pusan National University School of Medicine, Yangsan, Korea. saylee@pnu.edu.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32202085

Citation

Tak, Young Jin, and Sang Yeoup Lee. "Anti-Obesity Drugs: Long-Term Efficacy and Safety: an Updated Review." The World Journal of Men's Health, 2020.
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2020.
Tak, Y. J., & Lee, S. Y. (2020). Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. The World Journal of Men's Health. https://doi.org/10.5534/wjmh.200010
Tak YJ, Lee SY. Anti-Obesity Drugs: Long-Term Efficacy and Safety: an Updated Review. World J Mens Health. 2020 Mar 9; PubMed PMID: 32202085.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. AU - Tak,Young Jin, AU - Lee,Sang Yeoup, Y1 - 2020/03/09/ PY - 2020/01/13/received PY - 2020/02/05/revised PY - 2020/02/16/accepted PY - 2020/3/24/entrez KW - Liraglutide KW - Lorcaserin KW - Naltrexone/bupropion KW - Obesity KW - Orlistat KW - Phentermine/topiramate JF - The world journal of men's health JO - World J Mens Health N2 - As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically significant weight loss. Increasing evidence has shown that behavior-based interventions with one of these medications can result in greater weight loss than that elicited by usual care conditions. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). However, they have a high cost and may cause adverse outcomes depending on the individual. Very recently, on February 13, 2020, the US Food and Drug Administration requested withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. Therefore the decision to initiate drug therapy in obese individuals should be made after the benefits and risks are considered. Thereafter, treatment should be tailored to specific patient subpopulations depending on their chronic conditions, comorbidities, and preferences. Herein, we provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control. SN - 2287-4208 UR - https://www.unboundmedicine.com/medline/citation/32202085/Anti-Obesity_Drugs:_Long-Term_Efficacy_and_Safety:_An_Updated_Review L2 - https://wjmh.org/DOIx.php?id=10.5534/wjmh.200010 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.